China's Biopharmaceutical Industry Achieves Leapfrog Development as Multinational Pharma Giants Expand Investments

　　【Pharmaceutical Network Industry DynamicsIn recent years, China's biopharmaceutical industry has achieved leapfrog development. Among this, the number of multinational companies purchasing R&D projects from Chinese enterprises has been increasing. Data shows that since 2023, there have been more than 70 such deals, with a total transaction value of nearly 40 billion US dollars. Relevant professionals indicate that China has many favorable conditions for developing the biopharmaceutical industry and welcomes multinational pharmaceutical companies to continue expanding their investments in China, purchase more locally developed projects, and provide Chinese patients with more advanced treatment options.
 

It is reported that in recent years, many multinational pharmaceutical companies have expanded their investments in China. For instance, a representative from the multinational pharmaceutical company Takeda stated that China is a very important strategic market for them. China has a large population base; its healthcare system is continuously improving, and the demand for high-quality medicines is growing; the medical regulatory environment has also made significant progress. This will help multinational pharmaceutical companies like Takeda bring innovative drugs to Chinese patients more quickly.
 

A Takeda-related representative stated that the "Expand China" strategy currently being implemented means that every development project by Takeda can be advanced simultaneously in China. It is understood that the Takeda Asia-Pacific R&D Center, located in Shanghai, is deeply involved in Takeda's global new drug development. Currently, the Takeda Asia-Pacific R&D Center has achieved 100% participation in key clinical trials and approximately 50% participation in early-stage trials.
 

AstraZeneca, a multinational pharmaceutical company, is also actively expanding its presence in China. Recently, AstraZeneca officially announced that Shanghai has become its fifth global strategic center. Shanghai, China will join the ranks of four other major research and development-focused strategic centers—Cambridge in the UK, Boston and Gaithersburg in the US, and Gothenburg in Sweden—as another comprehensive global strategic hub integrating R&D, commercial operations, and manufacturing. It will serve as a key strategic pivot for AstraZeneca’s global strategy, R&D, and long-term development. Additionally, AstraZeneca will establish Shanghai as an important R&D base for cell therapy, working closely with Chinese innovation partners to actively promote broad collaboration in this field.
 

AstraZeneca-related personnel stated that Chinese innovation plays a key role in the global research, development, and production of important drugs. For AstraZeneca, the Chinese market is crucial.
 

Bayer is also one of the earliest multinational companies to enter China. In recent years, Bayer has continuously increased its investment in China. For instance, last year, Bayer's innovation hub in China — the Bayer · Yizhuang Open Innovation Center — was inaugurated and launched in Beijing. Meanwhile, Bayer's Imaging Diagnostic Beijing plant officially went into operation. Additionally, the construction of Bayer Crop Science’s new supply center in Hangzhou, with an investment exceeding 300 million yuan in partnership with the Qiantang District Government of Hangzhou, was successfully initiated in 2023.
 

When Germany's Merck Group released its 2023 earnings report at its headquarters in Darmstadt on the 7th, relevant representatives stated that China is a strategic market for Merck, and Merck is willing to continue investing and developing in China. The representative also expressed satisfaction with Merck's performance and market position in China, stating that the Chinese market will continue to bring development opportunities to the company. Merck is willing to further invest and expand its business areas in China.
 

Boston Scientific is also actively stepping up its layout in China. On March 27, the company held a groundbreaking ceremony for its manufacturing base in Lingang Smart Park Phase 10 C10, Shanghai, marking a significant step closer to achieving local production in China and reinforcing its localization strategy. According to reports, Boston Scientific's manufacturing base officially signed and settled in the Life Blue Bay specialty industrial park in Lingang New Area last October. Establishing its own production lines and accelerating local manufacturing are key components of Boston Scientific’s strategy to solidify its presence in Shanghai and fully implement its localization plan.
 

Industry insiders said that China, with its large population, is a major global consumer market. As the economy develops and income levels rise, people’s demand in the health sector is growing rapidly. At the same time, relevant Chinese authorities are actively researching and exploring policies to support the innovative drug industry throughout the entire life cycle of biopharmaceuticals, promoting the coordinated development and governance of medical insurance, healthcare, and pharmaceuticals… All these favorable conditions have attracted many multinational pharmaceutical companies to establish and expand their investments in China.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.